학술논문

Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer
Document Type
article
Source
Breast Cancer Research. 17(1)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Cancer
Women's Health
Breast Cancer
4.1 Discovery and preclinical testing of markers and technologies
Adult
Aged
Aged
80 and over
Biomarkers
Tumor
Breast Neoplasms
Carcinoma
Intraductal
Noninfiltrating
Chromosome Aberrations
DNA Copy Number Variations
Female
Genetic Predisposition to Disease
Humans
In Situ Hybridization
Fluorescence
Middle Aged
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Staging
Young Adult
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
IntroductionScreening mammography has contributed to a significant increase in the diagnosis of ductal carcinoma in situ (DCIS), raising concerns about overdiagnosis and overtreatment. Building on prior observations from lineage evolution analysis, we examined whether measuring genomic features of DCIS would predict association with invasive breast carcinoma (IBC). The long-term goal is to enhance standard clinicopathologic measures of low- versus high-risk DCIS and to enable risk-appropriate treatment.MethodsWe studied three common chromosomal copy number alterations (CNA) in IBC and designed fluorescence in situ hybridization-based assay to measure copy number at these loci in DCIS samples. Clinicopathologic data were extracted from the electronic medical records of Stanford Cancer Institute and linked to demographic data from the population-based California Cancer Registry; results were integrated with data from tissue microarrays of specimens containing DCIS that did not develop IBC versus DCIS with concurrent IBC. Multivariable logistic regression analysis was performed to describe associations of CNAs with these two groups of DCIS.ResultsWe examined 271 patients with DCIS (120 that did not develop IBC and 151 with concurrent IBC) for the presence of 1q, 8q24 and 11q13 copy number gains. Compared to DCIS-only patients, patients with concurrent IBC had higher frequencies of CNAs in their DCIS samples. On multivariable analysis with conventional clinicopathologic features, the copy number gains were significantly associated with concurrent IBC. The state of two of the three copy number gains in DCIS was associated with a risk of IBC that was 9.07 times that of no copy number gains, and the presence of gains at all three genomic loci in DCIS was associated with a more than 17-fold risk (P = 0.0013).ConclusionsCNAs have the potential to improve the identification of high-risk DCIS, defined by presence of concurrent IBC. Expanding and validating this approach in both additional cross-sectional and longitudinal cohorts may enable improved risk stratification and risk-appropriate treatment in DCIS.